Maze Therapeutics (NASDAQ:MAZE) Now Covered by Leerink Partners

Leerink Partners initiated coverage on shares of Maze Therapeutics (NASDAQ:MAZE) in a note issued to investors on Tuesday,Benzinga reports. The firm set an “outperform” rating and a $28.00 price target on the stock. Leerink Partners’ target price would indicate a potential upside of 139.32% from the company’s current price.

Maze Therapeutics Trading Up 10.7 %

NASDAQ MAZE opened at $11.70 on Tuesday. Maze Therapeutics has a 12-month low of $10.08 and a 12-month high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.